REGENXBIO to Present at Upcoming Investor Conferences

ROCKVILLE, Md., Aug. 31, 2017 (GLOBE NEWSWIRE) --  REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following September investor conferences:

Citi 12th Annual Biotech ConferenceDates: Wednesday, September 6 – Thursday, September 7Location: Mandarin Oriental, BostonPanel: Gene Therapy Manufacturing and Regulatory Opportunities and Challenges; Thursday, September 7, 2017 at 11:00 a.m. ET

Morgan Stanley 15th Annual Global Healthcare ConferenceDates: Monday, September 11 – Wednesday, September 13Location: Grand Hyatt, New YorkFireside chat: Wednesday, September 13, 2017 at 11:05 a.m. ET

Cantor Fitzgerald Global Healthcare ConferenceDates: Monday, September 25 – Wednesday, September 27Location: InterContinental New York Barclay Hotel, New YorkCompany presentation: Tuesday, September 26, 2017 at 4:00 p.m. ET

A live webcast of each presentation can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of each webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.

About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

CONTACT:

Investors
Heather Savelle, 646-395-3734
[email protected]

Media
Adam Pawluk, 202-591-4063
[email protected]

You May Also Be Interested In

• Cantor Fitzgerald Starts Milestone Pharmaceuticals (MIST) at Overweight
• CrowdStrike (CRWD) PT Adjusted $250 at Cantor Fitzgerald Post Stock Split
• Apollo Atomics Secures $31 Million to Turn Proven Reactor Technology Into a Factory-Built Product